N-terminal PEG-TRAIL Conjugates for Stability and Half-life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Native TRAIL has issues with low trimer formation ratio, cytotoxicity to normal cells, short half-life, low solubility, and stability, limiting its clinical applicability as a therapeutic agent for cancer and autoimmune diseases.
Innovation Solution
Development of N-terminal modified PEG-TRAIL conjugates, where PEG is bound to the N-terminus of TRAIL, enhancing trimer formation, stability, and solubility, and reducing hepatoxicity, with a pegylation method that includes using methoxypolyethylene glycol derivatives to extend serum half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native TRAIL is used as a therapeutic agent, then it can induce apoptosis in cancer cells through TRAIL receptors, but it has low trimer formation ratio and short half-life limiting its effectiveness
Solution Approach 1:
The patent creates a composite structure by fusing TRAIL with a dimeric zinc finger motif containing cysteine residues that coordinate zinc ions. This composite design forces trimer formation through zinc ion bridging between cysteine residues, achieving high trimer formation ratio while the PEGylation extends half-life by reducing renal clearance.
Solution Approach 2:
The patent modifies the molecular structure by adding a dimeric zinc finger motif with specific cysteine residues that change the coordination parameters to bind zinc ions. This structural parameter change enables trimerization, and further PEGylation changes the hydrodynamic radius and renal filtration parameters to extend half-life.
2Productivity
If native TRAIL is administered to treat cancer, then it shows high anticancer activity, but it causes cytotoxicity to normal cells such as hepatocytes and keratinocytes
Solution Approach 1:
The patent applies PEGylation specifically to the N-terminus of TRAIL, creating local modification that sterically protects normal cells from cytotoxicity while preserving the apoptotic function in cancer cells. The localized PEG shield reduces off-target effects without compromising the therapeutic action on tumor cells.
3Duration of action of moving object
If PEG is bound to the N-terminus of TRAIL to extend half-life, then serum half-life is prolonged and solubility is improved, but the molecular structure becomes more complex
Solution Approach 1:
The patent performs preliminary PEGylation at the N-terminus before administering TRAIL, which pre-extends the half-life and improves solubility. This preliminary modification ensures the drug is optimized for pharmacokinetics before entering the body, reducing the need for frequent dosing.
4Reliability
If TRAIL is used to treat cancer, then it induces apoptosis in various cancer cell types, but it has low solubility and poor stability in solution
Solution Approach 1:
The patent creates a composite of TRAIL with PEG polymer chains, where the hydrophilic PEG component improves solution stability and solubility while the TRAIL component maintains apoptosis induction capability. This composite structure prevents aggregation and enhances pharmacokinetic stability.
Data Source
AI summary
Disclosed herein are an N-terminal modified PEG-TRAIL conjugates and methods of making and using thereof. The PEG-TAIL conjugates have bioactivity that is substantially similar to that of native TRAIL coupled with an extended in vivo half-life and enhanced stability. The disclosed PEG-TRAIL conjugates exhibit significantly reduced hepatotoxicity when compared to that of non-PEGylated trimeric TRAIL. The disclosed methods of making the PEG-TRAIL conjugates provide a homogeneous, highly pure, form of N-terminal modified PEG-TRAIL. Compared to native TRAIL, the PEG-TRAIL conjugates exhibits high solubility and solution stability. The PEG-TRAIL conjugates are useful in preventing and treating proliferative or autoimmune diseases.